Gilead Sciences (NASDAQ:GILD) Given New $165.00 Price Target at Citigroup

Gilead Sciences (NASDAQ:GILD) had its price target increased by Citigroup from $156.00 to $165.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. Leerink Partners lifted their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Scotiabank raised their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $156.77.

Gilead Sciences Stock Up 0.0%

Shares of Gilead Sciences stock opened at $139.03 on Monday. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a 50 day moving average of $145.05 and a 200 day moving average of $130.79. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $172.57 billion, a P/E ratio of 20.54, a P/E/G ratio of 1.85 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 48.45%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider directly owned 131,779 shares in the company, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 299,280 shares of company stock worth $42,820,550 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. State Street Corp grew its position in shares of Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after acquiring an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the last quarter. Bank of America Corp DE grew its position in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $2,617,152,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley raised its outlook and nudged its price target higher as the firm updated biopharma models, keeping an Overweight rating — a third‑party endorsement that can support share gains. Morgan Stanley Boosts Gilead Outlook
• Positive Sentiment: Citigroup raised its price target on GILD to $165 with a Buy rating, signaling ~19% upside vs. the referenced price — analysts’ target upgrades tend to provide near‑term support. Citigroup Raises Gilead PT
• Positive Sentiment: Gilead expanded a multi‑year oncology R&D collaboration with Tempus AI, which could accelerate drug discovery/clinical targeting in oncology and improve the pipeline’s long‑term value. Gilead, Tempus AI Expand Collaboration
• Neutral Sentiment: Coverage pieces reviewing Q4 results placed Gilead among therapeutics peers; Gilead beat Q4 EPS and guided FY26 EPS, which is constructive but already priced in for many investors. Q4 Earnings Review vs Peers
• Neutral Sentiment: A profile on Gilead’s CCO about management style is market‑neutral human‑interest coverage; little direct impact on fundamentals. Fortune: Exec Prefers Energy Management
• Negative Sentiment: Activist group AHF staged protests and publicly blasted Gilead over HIV/AIDS drug pricing, increasing regulatory and reputational risk — this can pressure valuation and invite political scrutiny or pricing concessions. AHF Protests Gilead Over Pricing
• Negative Sentiment: Cantor Fitzgerald cut its price target to $115, a notable downgrade that adds selling pressure and signals differing analyst views on growth/valuation. Cantor Fitzgerald Lowers PT
• Negative Sentiment: Clinical wins from Allogene’s off‑the‑shelf CAR‑T program (interim MRD data) highlight competitive risk in the CAR‑T/oncology space — potential market share pressure where Gilead competes via Kite’s products. Allogene ALPHA3 Interim Results

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.